Slate Medicines | $130,000,000 | (Feb 25, 2026)
Letter AI | $40,000,000 | (Feb 25, 2026)
Subject | $28,000,000 | (Feb 25, 2026)
Certified by Founder
Lodge
Volastra Therapeutics
start up
United States
- New York, New York
- 08/03/2023
- Series A
- $60,000,000
Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is rapidly developing and implementing new methods to exploit this vulnerability. Leveraging its proprietary CINtech platform, the company is advancing a novel synthetic lethal and immune activating pipeline.
- Industry Biotechnology
- Website https://www.volastratx.com/
- LinkedIn https://www.linkedin.com/company/volastra-therapeutics/people/
KrisAtWork | $3,000,000 | (Feb 25, 2026)
Centauri Therapeutics Limited | $8,107,170 | (Feb 25, 2026)
Slang AI | $36,000,000 | (Feb 25, 2026)
Brilliant Harvest Inc. | $4,000,000 | (Feb 25, 2026)
Koah | $20,500,000 | (Feb 25, 2026)
Nimble | $47,000,000 | (Feb 25, 2026)
General Magic | $7,200,000 | (Feb 25, 2026)
Circadian Risk Inc. | $6,000,000 | (Feb 25, 2026)
Neural Earth | $9,300,000 | (Feb 25, 2026)
Jampack AI | $3,200,000 | (Feb 25, 2026)